Real-World Effectiveness of My Dose Coach™-Assisted Basal Insulin Titration in People with Type 2 Diabetes in Saudi Arabia and Kuwait

Introduction: My Dose Coach (MDC) is a digital smartphone application approved in multiple countries, including Saudi Arabia and Kuwait, to help people with type 2 diabetes (T2D) titrate their basal insulin as per their clinician-guided, individualized diabetes care plan. Methods: A retrospective, observational cohort analysis was conducted on MDC user data collected from 1 January 2021 to 1 June 2023 in Saudi Arabia and Kuwait. Primary outcome was change in fasting blood glucose (FBG). Key secondary outcomes included time to achieve FBG and HbA_1c targets, and time to first hypoglycemia event. Outcomes were analyzed by FBG target status and frequency of MDC usage (high: > 3 days per week; moderate: > 1– ≤ 3 days per week; low: ≤ 1 day per week). Results: Among all users (N = 494), mean ± SD FBG decrease was −44.4 ± 72.5 mg/dL. Mean ± SD time to achieve FBG target was 14.8 ± 20.9 days and 12.8 ± 18.8, 29.1 ± 28.0, and 43.5 ± 41.7 days for high-, moderate-, and low-frequency MDC users, respectively. Individualized FBG targets were achieved by 276 (55.9%) users, and high-frequency of MDC use was associated with better target achievement (p < 0.01). Mean ± SD time to achieve HbA_1c target was 48.0 ± 40.5 days. Reduction in HbA_1c was more in high-frequency MDC users (18.3%) than low-frequency MDC users (6.3%). Mean ± SD time to the first hypoglycemia event was 4.86 ± 4.8 days. Hypoglycemia events were reported in only seven (1.4%) participants and not significantly correlated with MDC use frequency (p = 0.1431). Conclusions: Current findings show that using MDC is associated with improved glycemic control in people with T2D in Saudi Arabia and Kuwait, with greater benefits observed with higher frequency MDC usage.